Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTNNB1 | P35222 | 9/20 | 0.52 |
| ▸ | TCF7L2 | Q9NQB0 | 9/20 | 0.52 |
| ▸ | BCHE | P06276 | 3/20 | 0.52 |
| ▸ | ACHE | P22303 | 3/20 | 0.52 |
| ▸ | SLC2A1 | P11166 | 1/20 | 0.47 |
| ▸ | EGFR | P00533 | 1/20 | 0.47 |
| ▸ | APP | P05067 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | HTT | P42858 | 1/20 | 0.43 |
| ▸ | TACR3 | P29371 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22165144 | 1.00 | CTNNB1 (0.52) | CTNNB1TCF7L2BCHEACHESLC2A1 | |
| SCHEMBL22164649 | 0.86 | APP (0.63) | EGFRAPPHTTTACR3 | |
| SCHEMBL29399234 | 0.86 | APP (0.63) | EGFRAPPHTTTACR3 | |
| SCHEMBL22165166 | 0.86 | HTT (0.49) | CTNNB1TCF7L2EGFRAPPMEN1 | |
| SCHEMBL22170000 | 0.84 | CTNNB1 (0.50) | CTNNB1TCF7L2EGFRAPP | |
| SCHEMBL29397324 | 0.81 | EGFR (0.72) | EGFRMEN1KMT2AHTT | |
| SCHEMBL22166042 | 0.81 | EGFR (0.72) | EGFRMEN1KMT2AHTT | |
| Formic Acid SCHEMBL29395376 | 0.80 | CTNNB1 (0.49) | CTNNB1TCF7L2 | |
| Formic Acid SCHEMBL22164697 | 0.80 | CTNNB1 (0.49) | CTNNB1TCF7L2 | |
| SCHEMBL2590209 | 0.79 | EGFR (0.69) | BCHEACHESLC2A1EGFRAPP |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | RIBOSCIENCE LLC | 2022-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220056052-A1 | QUINAZOLINE DERIVATIVES AS ECTONUCLEOTIDE PYROPHOSPHATASE PHOSPHODIESTERASE 1 INHIBITORS | ENPP1, ENPP3, PDE7A | CTNNB1 4724/4885TCF7L2 4452/4885BCHE 952/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.